Highlights Immunovia AB London S.E.

Equities

0G8X

SE0006091997

Market Closed - London S.E. Other stock markets 03:43:42 21/03/2024 pm IST			5-day change	1st Jan Change
1.4 ^SEK	-96.26%		-.--%	-22.82%

21/05	Immunovia Seeks SEK70 Million from Proposed Rights Offering	MT
29/04	Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina	29/04	CI
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test	22/04	CI
Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test	09/04	MT
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study	09/04	CI
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02	CI
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023	21/02	CI
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development	07/11	CI
Immunovia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/23/30	CI
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection	12/23/12	CI
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23	CI
Immunovia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23/23/23	CI
Immunovia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23/23/23	CI
Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test	19/23/19	CI
Immunovia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Sweden's Immunovia Forms R&D Partnership With Switzerland's Proteomedix	17/22/17	MT
Immunovia Launches Strategic Partnership with Proteomedix to Leverage R&D Efforts with Increased Focus on Commercialization	17/22/17	CI
Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d	12/22/12	CI
Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test	26/22/26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immunovia AB London S.E.

Equities

0G8X

SE0006091997

Highlights

Filters